Details of the Drug

General Information of Drug (ID: DMQXTJS)

• Drug Name: Eptifibatide
• Synonyms: Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute cardiac ischemic events	BA40.Z	Approved	[1]
Acute coronary syndrome	BA41	Approved	[2]
Pneumonia	CA40	Approved	[2]

• Therapeutic Class: Anticoagulants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 4:
  Molecular Weight (mw); 832
  Logarithm of the Partition Coefficient (xlogp); -2.4
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 10
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.2 mL/min/kg [4]
  Elimination: 50% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.5 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.678 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.75% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.17 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 65 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Surgical and medical procedures	Not Available	ITGA2B	OT4Y17PY	[6]
Surgical and medical procedures	Not Available	ITGB3	OTWCK1K6	[6]

• Chemical Identifiers:
  Formula: C35H49N11O9S2
  IUPAC Name: 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
  Canonical SMILES: C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
  InChI: InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
  InChIKey: CZKPOZZJODAYPZ-LROMGURASA-N
• Cross-matching ID:
  PubChem CID: 448812
  ChEBI ID: CHEBI:291902
  CAS Number: 188627-80-7
  DrugBank ID: DB00063
  TTD ID: D09ZIO
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	TT38RM1	ITA2B_HUMAN ; ITB3_HUMAN	Modulator	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Gene/Protein Processing	[8]
CD40 ligand (CD40LG)	OT75Z6A6	CD40L_HUMAN	Gene/Protein Processing	[8]
Integrin alpha-IIb (ITGA2B)	OT4Y17PY	ITA2B_HUMAN	Drug Response	[6]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Drug Response	[6]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Gene/Protein Processing	[8]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Gene/Protein Processing	[8]

Molecular Expression Atlas of This Drug

• The Studied Disease: Acute cardiac ischemic events
• ICD Disease Classification: BA40.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	DTT	ITGA2B; ITGB3	7.83E-01	-0.11	-0.45

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Eptifibatide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Vitamin E	DMZC90K	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Vitamin E.	Cardiovascular disease [BA00-BE2Z]	[9]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Pentosan polysulfate.	Chronic pain [MG30]	[10]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Phenylbutazone.	Chronic pain [MG30]	[11]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Ketoprofen.	Chronic pain [MG30]	[11]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Levomilnacipran.	Chronic pain [MG30]	[12]
Anisindione	DM2C48U	Major	Increased risk of bleeding by the combination of Eptifibatide and Anisindione.	Coagulation defect [3B10]	[11]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Eptifibatide and Regorafenib.	Colorectal cancer [2B91]	[13]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Intedanib.	Colorectal cancer [2B91]	[14]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Eptifibatide and Ardeparin.	Coronary thrombosis [BA43]	[15]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Eptifibatide and Danaparoid.	Deep vein thrombosis [BD71]	[15]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Eptifibatide and Rivaroxaban.	Deep vein thrombosis [BD71]	[16]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Sertraline.	Depression [6A70-6A7Z]	[12]
Fluoxetine	DM3PD2C	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Fluoxetine.	Depression [6A70-6A7Z]	[12]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Vilazodone.	Depression [6A70-6A7Z]	[12]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Paroxetine.	Depression [6A70-6A7Z]	[12]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Vortioxetine.	Depression [6A70-6A7Z]	[12]
Duloxetine	DM9BI7M	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Duloxetine.	Depression [6A70-6A7Z]	[12]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Milnacipran.	Depression [6A70-6A7Z]	[12]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Escitalopram.	Depression [6A70-6A7Z]	[12]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Desvenlafaxine.	Depression [6A70-6A7Z]	[12]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Clomipramine.	Depression [6A70-6A7Z]	[12]
Fluvoxamine	DMQTJSX	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Fluvoxamine.	Depression [6A70-6A7Z]	[12]
Venlafaxine	DMR6QH0	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Venlafaxine.	Depression [6A70-6A7Z]	[12]
Heme	DMGC287	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Heme.	Discovery agent [N.A.]	[17]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Eptifibatide and Apigenin.	Discovery agent [N.A.]	[18]
Citalopram derivative 1	DMITX1G	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Citalopram derivative 1.	Discovery agent [N.A.]	[12]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Eptifibatide and PMID28870136-Compound-49.	Discovery agent [N.A.]	[19]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[12]
Suprofen	DMKXJZ7	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Suprofen.	Eye anterior segment structural developmental anomaly [LA11]	[20]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Mefenamic acid.	Female pelvic pain [GA34]	[11]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Eptifibatide and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Tipranavir	DM8HJX6	Major	Increased risk of bleeding by the combination of Eptifibatide and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Dipyridamole	DMXY30O	Major	Increased risk of bleeding by the combination of Eptifibatide and Dipyridamole.	Hypertension [BA00-BA04]	[22]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[11]
Ticlopidine	DMO946V	Major	Increased risk of bleeding by the combination of Eptifibatide and Ticlopidine.	Ischaemic/haemorrhagic stroke [8B20]	[22]
Tositumomab	DMMYZ3D	Major	Increased risk of bleeding by the combination of Eptifibatide and Tositumomab.	Malignant haematopoietic neoplasm [2B33]	[23]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Eptifibatide and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[24]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Eptifibatide and Ibrutinib.	Mature B-cell lymphoma [2A85]	[25]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Eptifibatide and Ponatinib.	Mature B-cell lymphoma [2A85]	[26]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Eptifibatide and Panobinostat.	Multiple myeloma [2A83]	[27]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Eptifibatide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[28]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Eptifibatide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[10]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Eptifibatide and Prasugrel.	Myocardial infarction [BA41-BA43]	[22]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Eptifibatide and Vorapaxar.	Myocardial infarction [BA41-BA43]	[29]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Sibutramine.	Obesity [5B80-5B81]	[12]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Dexfenfluramine.	Obesity [5B80-5B81]	[12]
Diclofenac	DMPIHLS	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Diclofenac.	Osteoarthritis [FA00-FA05]	[11]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Nepafenac.	Osteoarthritis [FA00-FA05]	[20]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Naproxen.	Osteoarthritis [FA00-FA05]	[11]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Eptifibatide and MK-4827.	Ovarian cancer [2C73]	[13]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Aspirin.	Pain [MG30-MG3Z]	[30]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Etodolac.	Pain [MG30-MG3Z]	[11]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Diflunisal.	Pain [MG30-MG3Z]	[30]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Ibuprofen.	Pain [MG30-MG3Z]	[11]
Nabumetone	DMAT2XH	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Nabumetone.	Pain [MG30-MG3Z]	[11]
Piroxicam	DMTK234	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Piroxicam.	Pain [MG30-MG3Z]	[11]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[30]
Ketorolac	DMI4EL5	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Ketorolac.	Postoperative inflammation [1A00-CA43]	[11]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Bromfenac.	Postoperative inflammation [1A00-CA43]	[20]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Treprostinil.	Pulmonary hypertension [BB01]	[31]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Epoprostenol.	Pulmonary hypertension [BB01]	[31]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Iloprost.	Pulmonary hypertension [BB01]	[31]
Salsalate	DM13P4C	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Salsalate.	Rheumatoid arthritis [FA20]	[30]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Meloxicam.	Rheumatoid arthritis [FA20]	[11]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Sulindac.	Rheumatoid arthritis [FA20]	[11]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Oxaprozin.	Rheumatoid arthritis [FA20]	[11]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Flurbiprofen.	Rheumatoid arthritis [FA20]	[11]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Fenoprofen.	Rheumatoid arthritis [FA20]	[11]
Indomethacin	DMSC4A7	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Indomethacin.	Rheumatoid arthritis [FA20]	[11]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Tolmetin.	Rheumatoid arthritis [FA20]	[11]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[30]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Eptifibatide and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[32]
Warfarin	DMJYCVW	Major	Increased risk of bleeding by the combination of Eptifibatide and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[11]
Caplacizumab	DMPUKA7	Major	Increased risk of bleeding by the combination of Eptifibatide and Caplacizumab.	Thrombocytopenia [3B64]	[27]
Anagrelide	DMSQ8MD	Major	Increased risk of bleeding by the combination of Eptifibatide and Anagrelide.	Thrombocytosis [3B63]	[11]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Eptifibatide and Apixaban.	Thrombosis [DB61-GB90]	[13]
Cangrelor	DM8JRH0	Major	Increased risk of bleeding by the combination of Eptifibatide and Cangrelor.	Thrombosis [DB61-GB90]	[13]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Eptifibatide and Brilinta.	Thrombosis [DB61-GB90]	[13]
Argatroban	DMFI46A	Major	Increased risk of bleeding by the combination of Eptifibatide and Argatroban.	Thrombosis [DB61-GB90]	[33]
Dicumarol	DMFQCB1	Major	Increased risk of bleeding by the combination of Eptifibatide and Dicumarol.	Thrombosis [DB61-GB90]	[34]
Clopidogrel	DMOL54H	Major	Increased risk of bleeding by the combination of Eptifibatide and Clopidogrel.	Thrombosis [DB61-GB90]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Eptifibatide and Cabozantinib.	Thyroid cancer [2D10]	[35]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Eptifibatide and Betrixaban.	Venous thromboembolism [BD72]	[36]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6585).
• [2] Eptifibatide FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
• [8] Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
• [9] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al "Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status." Am J Clin Nutr 80 (2004): 143-8. [PMID: 15213041]
• [10] Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
• [11] Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
• [12] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [13] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [14] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [15] Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
• [16] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [17] Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
• [18] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
• [19] Canadian Pharmacists Association.
• [20] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [21] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [22] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
• [23] Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab). GlaxoSmithKline, Research Triangle Park, NC.
• [24] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [25] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [26] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [27] Cerner Multum, Inc. "Australian Product Information.".
• [28] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [29] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [30] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest 119(1 Suppl) (2001): 1S-2S. [PMID: 11157638]
• [31] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
• [32] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
• [33] Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
• [34] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36. [PMID: 14769198]
• [35] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [36] Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.